ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
17.25 ^USD	+1.47%		+3.23%	-44.91%

Apr. 30	UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating	MT
Apr. 23	Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	MT

Acadia Pharmaceuticals Inc. Announces Executive Changes

January 31, 2024 at 06:18 am EST

ACADIA Pharmaceuticals Inc. announced that Austin D. Kim, Executive Vice President and Secretary, will be leaving the Company to pursue other opportunities. Effective upon the appointment of his successor, Mr. Kim will remain employed by the Company as a non-executive employee for a period to be determined to assist with the orderly transition of duties and responsibilities to his successor.

Latest news about ACADIA Pharmaceuticals Inc.

UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating	Apr. 30	MT
Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	Apr. 22	MT
Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada	Apr. 22	MT
Acadia Pharmaceuticals Inc Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada	Apr. 22	CI
ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting	Apr. 17	CI
ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development	Apr. 02	CI
Acadia Pharmaceuticals Insider Sold Shares Worth $317,081, According to a Recent SEC Filing	Mar. 28	MT
JPMorgan Adjusts Price Target on ACADIA Pharmaceuticals to $25 From $29, Maintains Overweight Rating	Mar. 25	MT
Transcript : ACADIA Pharmaceuticals Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 02:00 PM	Mar. 18
UBS Adjusts ACADIA Pharmaceuticals Price Target to $33 From $35, Maintains Buy Rating	Mar. 13	MT
Morgan Stanley Cuts Price Target on ACADIA Pharmaceuticals to $30 From $40 After Failed Study of Pimavanserin in Negative Symptoms of Schizophrenia; Overweight Kept	Mar. 13	MT
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $22 From $24, Maintains Hold Rating	Mar. 12	MT
Cantor Fitzgerald Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $42, Maintains Overweight Rating	Mar. 12	MT
Sector Update: Health Care Stocks Gain Premarket Tuesday	Mar. 12	MT
Baird Adjusts Price Target on ACADIA Pharmaceuticals to $31 From $40, Maintains Outperform Rating	Mar. 12	MT
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell	Mar. 12	MT
Needham Lowers Price Target on ACADIA Pharmaceuticals to $32 From $36, Keeps Buy Rating	Mar. 12	MT
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $19 From $25, Maintains Perform Rating	Mar. 12	MT
Canaccord Genuity Adjusts Price Target on ACADIA Pharmaceuticals to $33 From $40, Keeps Buy Rating	Mar. 12	MT
JMP Securities Cuts ACADIA Pharmaceuticals Price Target to $39 From $44, Maintains Market Outperform Rating	Mar. 12	MT
Top Premarket Decliners	Mar. 12	MT
RBC Cuts Price Target on ACADIA Pharmaceuticals to $30 From $35 After Phase 3 Trial of Pimavanserin Fails to Reach Primary Endpoint; Outperform Kept	Mar. 12	MT
Mizuho Securities Downgrades ACADIA Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $25 From $39	Mar. 12	MT
North American Morning Briefing : Inflation Data Back in the Spotlight	Mar. 12	DJ

Chart ACADIA Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Sector

Biotechnology & Medical Research

Calendar

04:05pm - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ACADIA Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

17.25 USD

Average target price

28.75 USD

Spread / Average Target

+66.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACADIA PHARMACEUTICALS INC.	-44.91%	2.85B
MODERNA, INC.	+21.74%	46.4B
IQVIA HOLDINGS INC.	-0.97%	41.75B
LONZA GROUP AG	+49.17%	41.37B
CELLTRION, INC.	-3.52%	29.71B
ICON PUBLIC LIMITED COMPANY	+11.12%	26.01B
ALNYLAM PHARMACEUTICALS, INC.	-19.37%	19.52B
MEDPACE HOLDINGS, INC.	+31.18%	12.43B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.04%	12.13B
BIO-TECHNE CORPORATION	+0.39%	12.18B

Other Biotechnology & Medical Research